Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States

Conclusion: This real-world study demonstrated a significant economic burden in mCSPC patients, and a propensity to use ADT monotherapy in clinical practice despite the availability and guideline recommendations of advanced life-prolonging therapies.PMID:38420699 | DOI:10.1080/13696998.2024.2323901

Source: Journal of Medical Economics - February 29, 2024 Category: Health Management Authors: Deborah R Kaye Ibrahim Khilfeh Erik Muser Laura Morrison Frederic Kinkead Patrick Lefebvre Dominic Pilon Daniel George Source Type: research